Our results clearly show that oncogenic KrasGly12 mutations accumulate after caerulein-induced pancreatitis especially in Sirt2−/− mice possibly due to a growth advantage of oncogenic Kras mutation. The gene discussed is KRAS; the disease is pancreatitis.